Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia.

Al-Sawaf O, Herling CD, Holtick U, Scheid C, Cramer P, Sasse S, von Tresckow B, Tuchscherer A, Fischer K, Eichhorst B, Hallek M, Frenzel LP.

Haematologica. 2019 May;104(5):e224-e226. doi: 10.3324/haematol.2018.212837. Epub 2019 Feb 21. No abstract available.

2.

Management of an adult patient with sickle cell disease and acute chest syndrome by veno-venous extracorporeal membrane oxygenation.

Al-Sawaf O, Köhler P, Eichenauer DA, Böll B, Kochanek M, Shimabukuro-Vornhagen A.

Ann Hematol. 2019 Mar;98(3):789-791. doi: 10.1007/s00277-019-03596-z. Epub 2019 Jan 14. No abstract available.

PMID:
30643938
3.

CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.

von Tresckow J, Cramer P, Bahlo J, Robrecht S, Langerbeins P, Fink AM, Al-Sawaf O, Illmer T, Klaproth H, Estenfelder S, Ritgen M, Fischer K, Wendtner CM, Kreuzer KA, Stilgenbauer S, Böttcher S, Eichhorst BF, Hallek M.

Leukemia. 2019 May;33(5):1161-1172. doi: 10.1038/s41375-018-0313-8. Epub 2018 Dec 19.

PMID:
30568174
4.

Pelvic cellulitis caused by Raoultella planticola in a neutropenic patient.

Al-Sawaf O, Garcia-Borrega J, Vehreschild JJ, Thelen P, Fätkenheuer G, Shimabukuro-Vornhagen A, Kochanek M, Böll B.

J Infect Chemother. 2019 Apr;25(4):298-301. doi: 10.1016/j.jiac.2018.09.013. Epub 2018 Oct 25.

PMID:
30482700
5.

Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia.

Al-Sawaf O, Bahlo J, Robrecht S, Fischer K, Herling CD, Hoechstetter M, Fink AM, von Tresckow J, Langerbeins P, Cramer P, Stilgenbauer S, Wendtner CM, Eichhorst B, Hallek M, Goede V.

Br J Haematol. 2018 Dec;183(5):727-735. doi: 10.1111/bjh.15604. Epub 2018 Nov 21.

PMID:
30460980
6.

Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.

Cramer P, von Tresckow J, Bahlo J, Robrecht S, Langerbeins P, Al-Sawaf O, Engelke A, Fink AM, Fischer K, Tausch E, Seiler T, Fischer von Weikersthal L, Hebart H, Kreuzer KA, Böttcher S, Ritgen M, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, Hallek M.

Lancet Oncol. 2018 Sep;19(9):1215-1228. doi: 10.1016/S1470-2045(18)30414-5. Epub 2018 Aug 13.

PMID:
30115596
7.

Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.

Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, Jentsch-Ullrich K, Dörfel S, Fischer K, Wendtner CM, Nösslinger T, Ghia P, Bosch F, Kater AP, Döhner H, Kneba M, Kreuzer KA, Tausch E, Stilgenbauer S, Ritgen M, Böttcher S, Eichhorst B, Hallek M.

Lancet Haematol. 2017 Oct;4(10):e475-e486. doi: 10.1016/S2352-3026(17)30171-0. Epub 2017 Sep 12.

PMID:
28916311
8.

Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group.

Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, von Tresckow J, Maurer C, Bergmann M, Seiler T, Lange E, Kneba M, Stilgenbauer S, Döhner H, Kiehl MG, Jäger U, Wendtner CM, Fischer K, Goede V, Hallek M, Eichhorst B, Hopfinger G.

Leukemia. 2017 Oct;31(10):2251-2253. doi: 10.1038/leu.2017.221. Epub 2017 Jul 12. No abstract available.

PMID:
28745332
9.

Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review.

Al-Sawaf O, Cramer P, Goede V, Hallek M, Pflug N.

Ther Adv Hematol. 2017 Jun;8(6):197-205. doi: 10.1177/2040620717699365. Epub 2017 Mar 30. Review.

10.

Venetoclax and obinutuzumab in chronic lymphocytic leukemia.

Fischer K, Al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S, Kipps TJ, Weinkove R, Robinson S, Seiler T, Opat S, Owen C, López J, Humphrey K, Humerickhouse R, Tausch E, Frenzel L, Eichhorst B, Wendtner CM, Stilgenbauer S, Langerak AW, van Dongen JJM, Böttcher S, Ritgen M, Goede V, Mobasher M, Hallek M.

Blood. 2017 May 11;129(19):2702-2705. doi: 10.1182/blood-2017-01-761973. Epub 2017 Mar 21. No abstract available. Erratum in: Blood. 2017 Jul 13;130(2):232.

11.

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy.

Al-Sawaf O, Fischer K, Engelke A, Pflug N, Hallek M, Goede V.

Drug Des Devel Ther. 2017 Jan 25;11:295-304. doi: 10.2147/DDDT.S104869. eCollection 2017. Review.

12.

Targeted Therapy of CLL.

Al-Sawaf O, Fischer K, Eichhorst B, Hallek M.

Oncol Res Treat. 2016;39(12):768-778. Epub 2016 Nov 15. Review.

PMID:
27889784
13.

Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial.

Al-Sawaf O, Fischer K, Herling CD, Ritgen M, Böttcher S, Bahlo J, Elter T, Stilgenbauer S, Eichhorst BF, Busch R, Elberskirch U, Abenhardt W, Kneba M, Hallek M, Wendtner CM.

Eur J Haematol. 2017 Mar;98(3):254-262. doi: 10.1111/ejh.12825. Epub 2016 Dec 1.

PMID:
27862308
14.

Nrf2 in health and disease: current and future clinical implications.

Al-Sawaf O, Clarner T, Fragoulis A, Kan YW, Pufe T, Streetz K, Wruck CJ.

Clin Sci (Lond). 2015 Dec;129(12):989-99. doi: 10.1042/CS20150436. Review.

PMID:
26386022
15.

Nrf2 augments skeletal muscle regeneration after ischaemia-reperfusion injury.

Al-Sawaf O, Fragoulis A, Rosen C, Keimes N, Liehn EA, Hölzle F, Kan YW, Pufe T, Sönmez TT, Wruck CJ.

J Pathol. 2014 Dec;234(4):538-47. doi: 10.1002/path.4418. Epub 2014 Sep 16.

PMID:
25111334
16.

Nrf2 protects against TWEAK-mediated skeletal muscle wasting.

Al-Sawaf O, Fragoulis A, Rosen C, Kan YW, Sönmez TT, Pufe T, Wruck CJ.

Sci Rep. 2014 Jan 10;4:3625. doi: 10.1038/srep03625.

17.

A novel laser-Doppler flowmetry assisted murine model of acute hindlimb ischemia-reperfusion for free flap research.

Sönmez TT, Al-Sawaf O, Brandacher G, Kanzler I, Tuchscheerer N, Tohidnezhad M, Kanatas A, Knobe M, Fragoulis A, Tolba R, Mitchell D, Pufe T, Wruck CJ, Hölzle F, Liehn EA.

PLoS One. 2013 Jun 20;8(6):e66498. doi: 10.1371/journal.pone.0066498. Print 2013.

Supplemental Content

Loading ...
Support Center